Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Non-small Cell Lung Cancer Clinical Trial

Official title:

A Phase II Trial of Adjuvant Erlotinib in Patients With Resected, Early Stage Non-Small Cell Lung Cancer (NSCLC) With Confirmed Mutations in the Epidermal Growth Factor Receptor (EGFR)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00567359
• Other study ID #: 07-259
• Status: Completed
• Phase: Phase 2
• Start date: December 2007
• Est. completion date: December 2017

Study information

• Verified date: November 2018
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this research study erlotinib will be given to eligible participants whose lung cancer has been removed by surgery. Eligible patients have adenocarcinoma, a type of non-small lung cancer, and must have 1 or more of the following characteristics: be female, be of Asian or Pacific Rim descent and/or be a never smoker. The potential participant's tumor will be examined for Epidermal growth factor (EGFR) mutations. EGFR is a protein that is overexpressed in most non-small cell lung cancers. Some EGFR has been found to have specific mutations and the participant must have one of these mutations in his tumor.

Erlotinib blocks this protein and may control tumor growth and increase survival. Previous research has shown that erlotinib is most effective for people who have these specific mutations in the EGFR.

Description:

• Erlotinib is a pill taken daily and participants may continue to receive erlotinib for up to two years, as long as the cancer does not return and they do not experience any unacceptable side effects.

• While participants are receiving erlotinib, they will be asked to return to the clinic for study visits to monitor the status of their disease and their general health. For the first 5 months of erlotinib, they will return to the clinic monthly. After that they will return to the clinic every three months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologically confirmed diagnosis of NSCLC of adenocarcinoma histology

• Stage IA-B, IIA-B, or IIIA by the American Joint Committee on Cancer 7th edition staging criteria

• Patients must have undergone surgical resection with curative intent within 6 months of enrollment

• Sufficient tumor tissue available for EGFR mutation analysis

• At least ONE of the following patient characteristics: previously detected deletion 19 or L858R EGFR mutation, female sex, history of never smoking, or Asian/Pacific Rim ethnicity (to be enrolled in the screening portion of trial).

• 18 years of age or older

• Tumor samples must have either exon 19 deletion mutations or the exon 21 L858R point mutation

• ECOG Performance status of 0,1, or 2

• Adequate organ function as outlined in protocol

Exclusion Criteria:

• Radiographic evidence of recurrent NSCLC prior to erlotinib treatment

• Confirmed T790M resistance mutation in the primary tumor sample

• Prior exposure to EGFR tyrosine kinase inhibitors

• Known hypersensitivity to erlotinib, gefitinib, or any closely related drug

• Pregnant or breastfeeding women

• Any evidence of clinically active interstitial lung disease

• Current use of enzyme-inducing anti-epileptic drugs, including carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital, and primidone

• Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study

• Use of any non-FDA approved or investigational agent within 2 weeks of enrolling onto the trial, or failure to recover from the side effects of any of these agents

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• Erlotinib
Oral drug taken daily around the same time. Starting dose is 150mg once daily.

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hosptial	Boston	Massachusetts
United States	Taussig Cancer Center	Cleveland	Ohio
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	North Shore Medical Center	Peabody	Massachusetts
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Stanford University	Stanford	California

Sponsors (3)

Lead Sponsor	Collaborator
Massachusetts General Hospital	Dana-Farber Cancer Institute, Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	2-year Disease-free Survival	The number of participants alive and free from disease recurrence 2 years after enrollment. Participants were monitored for disease recurrence with the use of surveillance radiographs. When possible and medically appropriate, tissue biopsies were obtained to prove recurrence.	2 years
Secondary	Number of Participants With Treat Related Serious Adverse Events	Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 3.0) from the start of treatment until 30 days after the end of treatment. Serious adverse events were defined as adverse events that were grade 3 or greater and deemed to be possibly, probably or definitely related to the study treatment.	From the start of treatment until 30 days after the end of treatment, up 13 months total
Secondary	Median Overall Survival	The median amount of time from the time of registration until death due to any cause	From the time of registration until death, up to approximately 9 years
Secondary	Median Disease Free Survival	The median amount of time measured from the time of registration until the time of disease recurrence or death.	From registration to disease recurrence or death, up to approximately 9 years